Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / Apr / Biomarkers: The Bigger Picture
Oncology Liquid biopsy Biochemistry and molecular biology Oncology Genetics and epigenetics Insights

Biomarkers: The Bigger Picture

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

04/27/2022 Longer Read (pre 2022) 1 min read

Sponsored By

Share

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. DS Ettinger et al., “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021,” Natl Compr Canc Netw, 19, 254 (2021). PMID: 33668021.
  2. F Mosele et al., “Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group,” Ann Oncol, 31, 1491 (2020). PMID: 32853681.
  3. R Benayed et al., “High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden,” Clin Cancer Res, 25, 4712 (2019). PMID: 31028088.
  4. EE Heyer et al.,, “Diagnosis of fusion genes using targeted RNA sequencing,” Nat Commun, 10, 1388 (2019). PMID: 30918253.
  5. CB Westphalen et al., “Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population,” NPJ Precis Oncol, 5, 69 (2021). PMID: 34285332.
  6. C Marchiò et al., “ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research,” Ann Oncol, 30, 1417 (2019). PMID: 31268127.
  7. SW Lam et al., “Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing,” J Mol Diagn, 20, 653 (2018). PMID: 30139549.
  8. Z Zheng et al., “Anchored multiplex PCR for targeted next-generation sequencing,” Nat Med, 20, 1479 (2014). PMID: 25384085.
  9. J Lee et al., “Anchored Multiplex PCR Enables Sensitive and Specific Detection of Variants in Circulating Tumor DNA by Next-Generation Sequencing,” Cancer Genet, 214, 27 (2017).
  10. VA Papadimitrakopoulou et al., “Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study,” Ann Oncol, 29, viii741 (2018).
  11. NB Leighl et al., “Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer,” Clin Cancer Res, 25, 4691 (2019). PMID: 30988079.
  12. U Malapelle et al., “Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective,” J Mol Pathol, 2, 255 (2021).
  13. C Aggarwal et al., “Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer,” JAMA oncol, 5, 173 (2019). PMID: 30325992.

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

A Light in the Darkness
Liquid biopsy
A Light in the Darkness

March 4, 2022

2 min read

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

Biomarkers: The Bigger Picture
Liquid biopsy
Biomarkers: The Bigger Picture

April 27, 2022

1 min read

To unlock patient care, pathologists must focus on molecular pathology and ensure efficiency and effectiveness to improve testing. With this testing, patients can benefit from the best treatment to combat their disease.

Benchmarking… Liquid Biopsy
Liquid biopsy
Benchmarking… Liquid Biopsy

May 13, 2022

1 min read

A look at the last five years of publishing on liquid biopsy

Does Your Blood Know You Have Cancer?
Liquid biopsy
Does Your Blood Know You Have Cancer?

July 25, 2022

2 min read

Detection and monitoring are crucial for melanoma outcomes – could a blood test revolutionize both?

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.